
In today’s briefing:
- Mandom (4917 JP): When You Thought It Was Done, KKR Emerges as a Competing Bidder
- [Japan M&A] Nippon Life Shoots the Lights Out with a Bid at ¥1,693
- [Japan M&A] Nikkei Reports KKR Has Proposed an Overbid for Mandom (4917) At ¥2800+
- NS Group IPO Trading- Decent Institutional Demand
- Medical Data Vision (3902 JP): Nippon Life’s Tender Offer at JPY1,693 (3x Last Close)
- Matsuya R&D (7317 JP): Omron (6645 JP)’s Preconditional Tender Offer Is a Done Deal
- Marubeni (8002 JP): Re-Rating Done, Spot Copper Priced In
- Primer: Smaregi (4431 JP) – Dec 2025
- SanBio Co Ltd (4592 JP): Q3 FY01/26 flash update
- Primer: Hikari Tsushin (9435 JP) – Dec 2025

Mandom (4917 JP): When You Thought It Was Done, KKR Emerges as a Competing Bidder
- Mandom Corp (4917 JP) has disclosed that it has received a non-binding letter of intent from a third-party candidate, with purchase prices exceeding the CVC JPY2,520 offer.
- The Nikkei identifies the bidder as KKR and states that the offer is over JPY2,800, a 11.1% premium to the CVC offer. KKR want a Board-recommended offer.
- CVC has extended the close of its offer to 5 January 2026, but will need to revise terms as its irrevocables (particularly Murakami and Hibiki) can switch to KKR.
[Japan M&A] Nippon Life Shoots the Lights Out with a Bid at ¥1,693
- Over the weekend the Nikkei reported that Nippon Life would bid ¥60bn for Medical Data Vision (3902 JP). At one price per share, that meant ¥1,585.
- There is a deemed dividend treatment buyback for SBI at ¥1,189 which means they will end up with a capital loss (their in-price is ¥1,630) but they’ll offset that.
- This is the biggest win for minorities in a long while. Be happy.
[Japan M&A] Nikkei Reports KKR Has Proposed an Overbid for Mandom (4917) At ¥2800+
- The Nikkei came out post-close with an article saying that KKR had offered “more than 10%” (“higher than ¥2,800”) for Mandom Corp (4917 JP) vs the revised ¥2,520 CVC Bid.
- Mandom announced a revision to the Opinion Statement to include some but not a lot of details. That triggers an extension to the deal, closing 5 Jan vs 18 Dec.
- The language in the Mandom release is kind of interesting. This price gets us closer, but it may not be high enough.
NS Group IPO Trading- Decent Institutional Demand
- NS Group (471A JP) (NSG) is one of Japan’s leading rent guarantee service providers, offering payment guarantee and rent collection solutions to property owners and management companies.
- It raised around US$220m in its Japan IPO via an entirely secondary offering.
- In our previous note, we looked at its past performance and the deal dynamics. In this note, look at the trading dynamics.
Medical Data Vision (3902 JP): Nippon Life’s Tender Offer at JPY1,693 (3x Last Close)
- Medical Data Vision (3902 JP) has recommended a tender offer from Nippon Life at JPY1,693, a 212.4% premium to the last close.
- The substantial takeover premium reflects the outcome of an auction and SBI Holdings (8473 JP) willingness to share TOB tax benefits with minority shareholders.
- The substantial takeover premium also ensures that this is a done deal. The tender closes on 3 February, with payment commencing from 9 February.
Matsuya R&D (7317 JP): Omron (6645 JP)’s Preconditional Tender Offer Is a Done Deal
- Matsuya R&D (7317 JP) has recommended a preconditional tender offer from Omron Corp (6645 JP) at JPY1,110, a 22.8% premium to the last close price.
- While the offer represents an all-time high, it is light as it is 22% below the midpoint of the target IFA DCF valuation range.
- This is a done deal, as the lower limit is marginally above the level of irrevocables. Timing is the key risk with the offer expected to start in late June.
Marubeni (8002 JP): Re-Rating Done, Spot Copper Priced In
- Re-Rating delivered; stock now reflects spot copper (~$11.5k) and sustained mid-teens ROE, limiting multiple-led upside.
- Non-Resource platforms (leasing, agri) are stabilizing earnings; further upside depends on faster platform scaling and capital returns.
- Fair value ~¥4,550 on spot EPS; Hold bias with asymmetric downside if copper or FX turns.
Primer: Smaregi (4431 JP) – Dec 2025
- Smaregi is a high-growth, pure-play provider of cloud-based Point-of-Sale (POS) systems in Japan, capitalizing on the structural shift from legacy hardware to SaaS solutions among small and medium-sized businesses (SMBs).
- The company exhibits a robust financial profile, characterized by impressive revenue and earnings growth, expanding margins, and a rapidly growing base of high-margin Annual Recurring Revenue (ARR), which recently surpassed JPY 10 billion.
- While the company’s strategic focus on the underserved mid-sized retail and restaurant market presents a significant runway for growth, it faces intense competition and trades at a premium valuation, reflecting high investor expectations.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.
SanBio Co Ltd (4592 JP): Q3 FY01/26 flash update
- In cumulative Q3 FY01/26, the company reported no operating revenue and an operating loss of JPY2.7bn.
- The company forecasts a recurring loss of JPY4.5bn and a net loss of JPY4.0bn for FY01/26.
- R&D expenses increased to JPY2.8bn, reflecting sales preparation and manufacturing costs for AKUUGO® approval changes.
Primer: Hikari Tsushin (9435 JP) – Dec 2025
- Hikari Tsushin operates a diversified business model centered on recurring revenue streams from corporate and individual customers, with a strong focus on telecommunications, office automation, and energy services.
- The company has demonstrated a robust long-term growth track record, evidenced by double-digit compound annual growth in net income, EPS, and dividends over the past decade, alongside a strategic focus on shareholder returns through consistent dividend increases and buybacks.
- While revenue growth is solid, recent profitability has been hampered by rising Selling, General & Administrative (SG&A) expenses, leading to flat operating profit despite record top-line performance. This highlights a key challenge in managing costs amidst expansion.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

